Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 2/2020

01-04-2020 | osteosarcoma | Original Article

microRNA-138-5p as a Worse Prognosis Biomarker in Pediatric, Adolescent, and Young Adult Osteosarcoma

Authors: Gabriela Molinari Roberto, Regia Caroline Lira, Lara Elis Delsin, Gabriela Maciel Vieira, Marcela Oliveira Silva, Rodrigo Guedes Hakime, Mauricio Eiji Yamashita, Edgard Eduard Engel, Carlos Alberto Scrideli, Luiz Gonzaga Tone, María Sol Brassesco

Published in: Pathology & Oncology Research | Issue 2/2020

Login to get access

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor with two peaks of incidence, in early adolescence and the elderly. Patients affected with this malignancy often present metastatic disease at diagnosis, and despite multimodality therapy, survival has not improved substantially over the past 3 decades. Recently, miR-138-5p, proposed as a crucial intracellular mediator of invasion, has been recognized to target the Rho-associated coiled-coil containing protein kinase 2 (ROCK2). Dysregulation of ROCK1 and ROCK2 was also described in OS, being associated to higher metastasis incidence and worse prognosis. Nonetheless, the specific roles of miR-138-5p in pediatric and young adult OS and its ability to modulate these kinases remain to be established. Thus, in the present study, the expression levels miR-138-5p were evaluated in a consecutive cohort of exclusively pediatric and young adult primary OS samples. In contrast to previous reports that included adult tissues, our results showed upregulation of miR-138-5p associated with reduced event-free survival and relapsed cases. In parallel, ROCK1 mRNA levels were significantly reduced in tumor samples and negatively correlated with miR-138-5p. Similar correlations were observed after studying the profiles of ROCK1 and ROCK2 by immunohistochemistry. Our data present miR-138-5p as a consistent prognostic factor in pediatric and young adult OS, reinforcing its participation in the post-transcriptional regulation of ROCK kinases.
Literature
1.
Benjamin RS (2015) Osteosarcoma: better treatment through better trial design. Lancet Oncol 16(1):12–13PubMedCrossRef
2.
3.
Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004. Cancer 115:1531–1543PubMedCrossRef
4.
5.
Harting MT, Blakely ML (2006) Management of osteosarcoma pulmonary metastases. Semin Pediatr Surg 15:25–29PubMedCrossRef
6.
Isakoff MS, Bielack SS, Meltzer P, Gorlick R (2015) Osteosarcoma: current treatment and a collaborative pathway to success. J Clin Oncol 33:3029–3035PubMedPubMedCentralCrossRef
7.
8.
Liu X, Choy E, Hornicek FJ, Yang S, Yang C, Harmon D, Mankin H, Duan Z (2011) ROCK1 as a potential therapeutic target in osteosarcoma. J Orthop Res 29:1259–1266PubMedCrossRef
9.
10.
Fusella F, Ferretti R, Recupero D, Rocca S, Di Savino A, Tornillo G, Silengo L, Turco E, Cabodi S, Provero P, Pandolfi PP, Sapino A, Tarone G, Brancaccio M (2014) Morgana acts as a proto-oncogene through inhibition of a ROCK-PTEN pathway. J Pathol 234(2):152–163PubMed
11.
Lochhead PA, Wickman G, Mezna M, Olson MF (2010) Activating ROCK1 somatic mutations in human cancer. Oncogene 29:2591–2598PubMedCrossRef
12.
Zucchini C, Manara MC, Pinca RS, De Sanctis P, Guerzoni C, Sciandra M, Lollini P-L, Cenacchi G, Picci P, Valvassori L, Scotlandi K (2014) CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. Oncogene 33:1912–1921PubMedCrossRef
13.
Tan Y, Hu H, Tan W, Jin L, Liu J, Zhou H (2016) MicroRNA-138 inhibits migration and invasion of non-small cell lung cancer cells by targeting LIMK1. Mol Med Rep 14:4422–4428PubMedCrossRef
14.
Zhang J, Liu D, Feng Z, Mao J, Zhang C, Lu Y, Li J, Zhang Q, Li Q, Li L (2016) MicroRNA-138 modulates metastasis and EMT in breast cancer cells by targeting vimentin. Biomed Pharmacother 77:135–141PubMedCrossRef
15.
Jiang L, Liu X, Kolokythas A, Yu J, Wang A, Heidbreder CE, Shi F, Zhou X (2010) Downregulation of the Rho GTPase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer 127:505–512PubMedPubMedCentralCrossRef
16.
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods 25:402–408PubMedCrossRef
17.
Varghese F, Bukhari AB, Malhotra R, De A (2014) IHC profiler: an open source plugin for the quantitative evaluation and automated scoring of immunohistochemistry images of human tissue samples. PLoS One 9:e96801PubMedPubMedCentralCrossRef
18.
Li B, Yang X-X, Wang D, Ji H-K (2016) MicroRNA-138 inhibits proliferation of cervical cancer cells by targeting c-Met. Eur Rev Med Pharmacol Sci 20:1109–1114PubMed
19.
Liu X, Jiang L, Wang A, Yu J, Shi F, Zhou X (2009) MicroRNA-138 suppresses invasion and promotes apoptosis in head and neck squamous cell carcinoma cell lines. Cancer Lett 286:217–222PubMedPubMedCentralCrossRef
20.
Long L, Huang G, Zhu H, Guo Y, Liu Y, Huo J (2013) Down-regulation of miR-138 promotes colorectal cancer metastasis via directly targeting TWIST2. J Transl Med 11:275PubMedPubMedCentralCrossRef
21.
Mitomo S, Maesawa C, Ogasawara S, Iwaya T, Shibazaki M, Yashima-Abo A, Kotani K, Oikawa H, Sakurai E, Izutsu N, Kato K, Komatsu H, Ikeda K, Wakabayashi G, Masuda T (2008) Downregulation of miR-138 is associated with overexpression of human telomerase reverse transcriptase protein in human anaplastic thyroid carcinoma cell lines. Cancer Sci 99:280–286PubMedCrossRef
22.
Sun D-K, Wang J-M, Zhang P, Wang Y-Q (2015) MicroRNA-138 regulates metastatic potential of bladder Cancer through ZEB2. Cell Physiol Biochem 37:2366–2374PubMedCrossRef
23.
Xiao L, Zhou H, Li X-P, Chen J, Fang C, Mao C-X, Cui J-J, Zhang W, Zhou H-H, Yin J-Y, Liu Z-Q (2016) MicroRNA-138 acts as a tumor suppressor in non small cell lung cancer via targeting YAP1. Oncotarget 7:40038–40046PubMedPubMedCentralCrossRef
24.
Yu C, Wang M, Li Z, Xiao J, Peng F, Guo X, Deng Y, Jiang J, Sun C (2015) MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1. Cell Oncol (Dordr) 38:173–181CrossRef
25.
Wang Q, Tang H, Yin S, Dong C (2013) Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP-9. Oncol Rep 29:2046–2052PubMedCrossRef
26.
Yeh Y-M, Chuang C-M, Chao K-C, Wang L-H (2013) MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α. Int J Cancer 133:867–878PubMedCrossRef
27.
Jiang B, Mu W, Wang J, Lu J, Jiang S, Li L, Xu H, Tian H (2016) MicroRNA-138 functions as a tumor suppressor in osteosarcoma by targeting differentiated embryonic chondrocyte gene 2. J Exp Clin Cancer Res 35:69PubMedPubMedCentralCrossRef
28.
Lane J, Martin TA, Watkins G, Mansel RE, Jiang WG (2008) The expression and prognostic value of ROCK I and ROCK II and their role in human breast cancer. Int J Oncol 33:585–593PubMed
29.
Mertsch S, Thanos S (2014) Opposing signaling of ROCK1 and ROCK2 determines the switching of substrate specificity and the mode of migration of glioblastoma cells. Mol Neurobiol 49:900–915PubMedCrossRef
30.
Wu Y, Tang Y, Li Z, Li Z, Zhao Y, Wu Z, Su Q (2014) Expression and significance of Rac1, Pak1 and Rock1 in gastric carcinoma. Asia Pac J Clin Oncol 10:e33–e39PubMedCrossRef
31.
Takeba Y, Matsumoto N, Watanabe M, Takenoshita-Nakaya S, Ohta Y, Kumai T, Takagi M, Koizumi S, Asakura T, Otsubo T (2012) The rho kinase inhibitor fasudil is involved in p53-mediated apoptosis in human hepatocellular carcinoma cells. Cancer Chemother Pharmacol 69:1545–1555PubMedCrossRef
32.
Yang X, Di J, Zhang Y, Zhang S, Lu J, Liu J, Shi W (2012) The rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. Biomed Pharmacother 66:221–227PubMedCrossRef
33.
Storey JD, Madeoy J, Strout JL, Wurfel M, Ronald J, Akey JM (2007) Gene-expression variation within and among human populations. Am J Hum Genet 80:502–509PubMedPubMedCentralCrossRef
34.
Zhang W, Dolan ME (2008) Ancestry-related differences in gene expression: findings may enhance understanding of health disparities between populations. Pharmacogenomics 9:489–492PubMedCrossRef
35.
Scotting PJ, Walker DA, Perilongo G (2005) Opinion: childhood solid tumours: a developmental disorder. Nat Rev Cancer 5:481–488PubMedCrossRef
36.
Boissel N, Auclerc MF, Lhéritier V, Perel Y, Thomas X, Leblanc T, Rousselot P, Cayuela JM, Gabert J, Fegueux N, Piguet C, Huguet-Rigal F, Berthou C, Boiron JM, Pautas C, Michel G, Fière D, Leverger G, Dombret H, Baruchel A (2003) Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 21(5):774–780PubMedCrossRef
37.
Korshunov A, Remke M, Werft W, Benner A, Ryzhova M, Witt H, Sturm D, Wittmann A, Schöttler A, Felsberg J, Reifenberger G, Rutkowski S, Scheurlen W, Kulozik AE, von Deimling A, Lichter P, Pfister S (2010) Adult and pediatric Medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol 28:3054–3060PubMedCrossRef
38.
Northcott PA, Hielscher T, Dubuc A, Mack S, Shih D, Remke M, Al-Halabi H, Albrecht S, Jabado N, Eberhart CG, Grajkowska W, Weiss WA, Clifford SC, Bouffet E, Rutka JT, Korshunov A, Pfister S, Taylor MD (2011) Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol 122:231–240PubMedPubMedCentralCrossRef
39.
Paugh BS, Qu C, Jones C, Liu Z, Adamowicz-Brice M, Zhang J, Bax DA, Coyle B, Barrow J, Hargrave D, Lowe J, Gajjar A, Zhao W, Broniscer A, Ellison DW, Grundy RG, Baker SJ (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28:3061–3068PubMedPubMedCentralCrossRef
40.
Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A (2009) Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol 27:3391–3397PubMedCrossRef
41.
Akagi EM, Lavorato-Rocha AM, Maia B d M, Rodrigues IS, Carvalho KC, Stiepcich MM, Baiocchi G, Sato-Kuwabara Y, Rogatto SR, Soares FA, Rocha RM (2014) ROCK1 as a novel prognostic marker in vulvar cancer. BMC Cancer 14:822PubMedPubMedCentralCrossRef
42.
43.
Amaya CN, Mitchell DC, Bryan BA (2017) Rho kinase proteins display aberrant upregulation in vascular tumors and contribute to vascular tumor growth. BMC Cancer 17:485PubMedPubMedCentralCrossRef
44.
Islam M, Datta J, Lang JC, Teknos TN (2014) Down regulation of RhoC by microRNA-138 results in de-activation of FAK, Src and Erk1/2 signaling pathway in head and neck squamous cell carcinoma. Oral Oncol 50:448–456PubMedPubMedCentralCrossRef
Metadata
Title
microRNA-138-5p as a Worse Prognosis Biomarker in Pediatric, Adolescent, and Young Adult Osteosarcoma
Authors
Gabriela Molinari Roberto
Regia Caroline Lira
Lara Elis Delsin
Gabriela Maciel Vieira
Marcela Oliveira Silva
Rodrigo Guedes Hakime
Mauricio Eiji Yamashita
Edgard Eduard Engel
Carlos Alberto Scrideli
Luiz Gonzaga Tone
María Sol Brassesco
Publication date
01-04-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-019-00633-0

Other articles of this Issue 2/2020

Pathology & Oncology Research 2/2020 Go to the issue

Original Article

The Development and Application of Virtual Reality Animation Simulation Technology: Take Gastroscopy Simulation System as an Example

Original Article

All Benign and Malignant Apocrine Breast Lesions Over-Express Claudin 1 and 3 and Are Negative for Claudin 4

Original Article

Selective Inhibition of HIF1α Expression by ZnSO4 Has Antitumoral Effects in Human Melanoma

Letter to the Editor

Statin Therapy and Survival among Women with Ovarian Cancer: how much of it Is True?

Original Article

MicroRNA-182-5p Modulates Oral Squamous Cell Carcinoma Migration and Invasion Via Targeting MTSS1 Gene

Original Article

Phloretin Inhibits the Human Prostate Cancer Cells Through the Generation of Reactive Oxygen Species
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits